Harmony Biosciences Zacks Rank #1 Projects 21.4% Sales and 25.9% EPS Growth
Harmony Biosciences holds a Zacks Rank #1 with a Value Score of A, supported by a trailing four-quarter earnings surprise of 7.2%. Zacks Consensus projects 21.4% sales growth and 25.9% EPS growth for the current financial year, while shares have gained 4.6% over the past year.
1. Zacks Rank and Earnings Surprise
Harmony Biosciences carries a Zacks Rank #1 and a Value Score of A, reflecting strong analyst confidence in its fundamentals. The company achieved a trailing four-quarter earnings surprise of 7.2%, indicating consistent performance above consensus expectations.
2. Growth Projections and Share Performance
Zacks Consensus projects 21.4% revenue growth and 25.9% EPS growth for the current financial year. Shares of Harmony Biosciences have risen 4.6% over the past year, reflecting investor confidence in its growth outlook.